BackgroundHumanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent.MethodsPhase 1b study in patients with EpCAM-positive advanced solid tumors to determine the maximum tolerated dose (MTD) and safety profile of huKS-IL2 in combination with low-dose cyclophosphamide. Treatment consisted of cyclophosphamide (300mg/m2 on day 1), and escalating doses of h
Connor, Joseph P.; Cristea, Mihaela C.; Lewis, Nancy L.; and Lewis, Lionel D., "A Phase 1b Study of Humanized Ks-Interleukin-2 (Huks-Il2) Immunocytokine with Cyclophosphamide in Patients with Epcam-Positive Advanced Solid Tumors" (2013). Open Dartmouth: Faculty Open Access Articles. 2509.